Sign inCreate account

Report workspace tools

NCT00833963COMPLETEDanonymous

An Observational Study of Pregnancy and Pregnancy Outcomes in Women With Breast Cancer Treated With Herceptin, Perjeta in Combination With Herceptin, or Kadcyla During Pregnancy or Within 7 Months Prior to Conception

Sponsor

Source record

Genentech, Inc.

Phase

Source record

Not classified

Modality

AI-normalized

monoclonal antibody

Target

AI-normalized

Trastuzumab, Pertuzumab, Ado-Trastuzumab Emtansine

Indication / condition

AI-normalized

Breast Cancer

Intervention

Source record

Trastuzumab, Pertuzumab, Ado-Trastuzumab Emtansine

Source & freshness

Source record

NCT ID

NCT00833963

Original source

ClinicalTrials.gov

Source last updated

May 16, 2019

Ingested at

May 21, 2026

Internal sync

May 23, 2026

Model version

trialsignal-ai-v1

Normalized confidence

96%

Validation status

validated

Open original registry record
View original source fields

NCT ID

NCT00833963

Title

An Observational Study of Pregnancy and Pregnancy Outcomes in Women With Breast Cancer Treated With Herceptin, Perjeta in Combination With Herceptin, or Kadcyla During Pregnancy or Within 7 Months Prior to Conception

Sponsor

Genentech, Inc.

Status

COMPLETED

Phase

Detailed source ingestion pending

Condition raw

Breast Cancer, Pregnancy

Condition normalized

Breast Cancer, Pregnancy

Modality raw

monoclonal antibody

Modality normalized

monoclonal antibody

Target raw

Trastuzumab, Pertuzumab, Ado-Trastuzumab Emtansine

Target normalized

Trastuzumab, Pertuzumab, Ado-Trastuzumab Emtansine

Interventions

Trastuzumab, Pertuzumab, Ado-Trastuzumab Emtansine

Public preview

Source record

The MotHER Pregnancy Registry is a United States (U.S.)-based, prospective, observational cohort study in women with breast cancer who have been or are being treated with a trastuzumab (herceptin)-containing regimen with or without pertuzumab (perjeta) or ado-trastuzumab emtansine (kadcyla) during pregnancy or within 7 months prior to conception (regardless of cancer stage at the time of trastuzumab, pertuzumab, or ado-trastuzumab emtansine exposure).

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections
Patent/IP landscape with verified records when available
Board-ready PDF export with source provenance
Save to folders and synthesize multiple assets in premium workspace
Create account
Sign in

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

An Observational Study of Pregnancy and Pregnancy Outcomes in Women With Breast Cancer Treated With Herceptin, Perjeta in Combination With Herceptin, or Kadcyla During Pregnancy or Within 7 Months Prior to Conception

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 13, 2026

NCT ID

NCT00833963

Status

COMPLETED

Phase

N/A

Sponsor

Genentech, Inc.

Executive brief

Investment-Ready Snapshot

The MotHER Pregnancy Registry is a United States (U.S.)-based, prospective, observational cohort study in women with breast cancer who have been or are being treated with a trastuzumab (herceptin)-containing regimen with or without pertuzumab (perjeta) or ado-trastuzumab emtansine (kadcyla) during pregnancy or within 7 months prior to conception (regardless of cancer stage at the time of trastuzumab, pertuzumab, or ado-trastuzumab emtansine exposure).

Source & freshness

Provenance

SourceClinicalTrials.gov
Source updatedMay 16, 2019
Internal syncMay 23, 2026
Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT00833963

Indication

Breast Cancer

Modality

monoclonal antibody

Target

Trastuzumab, Pertuzumab, Ado-Trastuzumab Emtansine

Intervention

Trastuzumab, Pertuzumab, Ado-Trastuzumab Emtansine

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.